NORVAX®
SHRIMPVIB
A major breakthrough in sustainable shrimp farming and disease prevention
was achieved by Intervet with the development and recent launch of the
world’s first commercial multivalent vaccine against vibriosis in shrimp.
Norvax® ShrimpVib is an inactivated multivalent and
uniquely adjuvanted vaccine for the enhanced resistence and protection of
penaeid shrimp against the major pathogenic Vibrio species infecting shrimp,
including the so-called luminous bacterial disease.
Norvax® ShrimpVib is easily incorporated into normal
hatchery practices as enrichment of Artemia nauplii (stage II) with the
vaccine is all that is required. The protection induced in the hatchery is
carried over into the critical stages in the grow-out phase (days 30 to 80
after transfer).
Field trials performed in Asia and South America have
proven the excellent efficacy of the vaccine as the survival, quality and
growth of the vaccinated shrimp were significantly improved compared with
non-vaccinated shrimp. In addition, the need for the use of costly and
environmentally-damaging antibiotics is reduced.
(from Intervet Aquatic Animal Health Newsletter,
October 2000, February 2001, June 2001; interesting information on methods
for bacteriological sampling; new vaccines for fish and shrimp; summarises
of scientific publications; from Intervet International bv, Aquatic Animal
Health Division, P.O. Box 31, 5830 AA Boxmeer, The Netherlands, Tel: +31 465
587.600; Fax: +31 485 577.333, e-mail info@intervet.com;
URL: www.intervet.com)